Ziopharm Oncology’s (ZIOP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Ziopharm Oncology (NASDAQ:ZIOP) in a research note released on Monday morning. The firm currently has a $5.50 target price on the biotechnology company’s stock.

“We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018.”,” HC Wainwright’s analyst commented.

Several other equities research analysts have also recently issued reports on ZIOP. ValuEngine cut shares of Ziopharm Oncology from a sell rating to a strong sell rating in a report on Thursday, March 1st. Zacks Investment Research cut shares of Ziopharm Oncology from a hold rating to a sell rating in a report on Saturday, March 3rd. Finally, BidaskClub upgraded shares of Ziopharm Oncology from a strong sell rating to a sell rating in a report on Wednesday, April 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $5.25.

NASDAQ:ZIOP opened at $4.45 on Monday. Ziopharm Oncology has a 52 week low of $4.42 and a 52 week high of $4.52. The company has a market cap of $644.78 million, a PE ratio of -8.40 and a beta of 1.74.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). The firm had revenue of $0.15 million for the quarter, compared to analysts’ expectations of $1.55 million. sell-side analysts forecast that Ziopharm Oncology will post -0.52 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Ziopharm Oncology by 3.4% in the fourth quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock worth $35,187,000 after purchasing an additional 280,003 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in Ziopharm Oncology in the fourth quarter worth approximately $338,000. Schwab Charles Investment Management Inc. boosted its holdings in Ziopharm Oncology by 4.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 644,642 shares of the biotechnology company’s stock worth $2,669,000 after purchasing an additional 26,053 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Ziopharm Oncology by 134.1% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 60,635 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 34,739 shares during the last quarter. Finally, G&S Capital LLC purchased a new stake in Ziopharm Oncology in the fourth quarter worth approximately $125,000. Institutional investors own 40.12% of the company’s stock.

About Ziopharm Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Receive News & Ratings for Ziopharm Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply